Filing Details
- Accession Number:
- 0000899243-23-004360
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-08 20:27:24
- Reporting Period:
- 2023-02-06
- Accepted Time:
- 2023-02-08 20:27:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1805387 | Cerevel Therapeutics Holdings Inc. | CERE | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1197018 | Anthony N Coles | C/O Cerevel Therapeutics Holdings, Inc. 222 Jacobs Street, Suite 200 Cambridge MA 02141 | Ceo And Chairperson | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-02-07 | 50,000 | $3.50 | 52,704 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-02-07 | 42,058 | $33.04 | 10,646 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-07 | 7,942 | $33.57 | 2,704 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2023-02-06 | 243,042 | $0.00 | 243,042 | $34.41 |
| Common Stock | Restricted Stock Units | Acquisiton | 2023-02-06 | 61,762 | $0.00 | 61,762 | $0.00 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-02-07 | 50,000 | $0.00 | 50,000 | $3.50 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 243,042 | 2033-02-06 | No | 4 | A | Direct | |
| 61,762 | No | 4 | A | Direct | ||
| 2,952,417 | 2028-12-24 | No | 4 | M | Direct |
Footnotes
- These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 - $33.43. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.44 - $34.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
- The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date.
- 25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
